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Abstract
The invasive characteristic of nonfunctional pituitary adenoma (NFPA) is an
important clinical problem without a clear molecular mechanism, which severely
challenges its treatment strategy. Clarification of the proteomic alterations between
invasive and non-invasive NFPAs is the key step for in-depth understanding of its
mechanisms and discovering reliably invasive biomarkers. Two-dimensional gel
electrophoresis (2DGE)-based comparative proteomics was carried out between
four invasive and four non-invasive NFPAs. A total of 64 upregulated protein-spots
and 39 downregulated protein-spots were identified among 24 (invasive n = 12;
non-invasive n = 12) 2DGE maps (ca. 1200 spots/gel). Mass spectrometry identified
30 upregulated proteins and 27 downregulated proteins between invasive and non-
invasive NFPAs. Those 57 differentially expressed proteins are involved in multiple
biological functions, including oxidative stress, mitochondrial dysfunction, MAPK
signaling alteration, proteolysis abnormality, CDK-C signaling, amyloid processing,
and TR/RXR activation. These findings provide important clues to insights into
molecular mechanisms of invasive NFPAs and to discovery of effective biomarkers
for effective treatment of invasive NFPA patients.
Keywords: invasive nonfunctional pituitary adenoma, two-dimensional gel
electrophoresis, mass spectrometry, proteome, comparative proteomics,
invasive biomarker
1. Introduction
Invasive pituitary adenoma is a type of pituitary adenoma that locally invades
contiguous anatomy structures surrounding pituitary gland [1–6]. In fact, the rate
of local invasion is about 40% of pituitary adenoma patients with macroscopic
observation, and even up to 80% of pituitary adenoma patients with microscopic
observation [1, 7, 8] although most pituitary adenomas are align. Magnetic reso-
nance imaging (MRI) is commonly used method to measure the size of pituitary
adenomas, and can classify pituitary adenomas into giant adenomas (>40 mm),
macro-plus adenomas (20–30 mm), macroadenomas (10–20 mm), and
microadenomas (<10 mm) [5, 7]. Furthermore, based on preoperative MRI and
perioperative observation, pituitary adenomas are classified into grade I (enclosed
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microadenoma, <10 mm), grade II (enclosed macroadenoma, >10 mm), grade III
(localized perforation of the sellar floor), and grade IV (diffuse destruction of the
sellar floor) [9]. Grades III and IV are commonly looked as invasive pituitary
adenomas. Invasiveness is very challenging clinical problem in pituitary adenoma
patient, which reasons are that (1) invasiveness suppresses and/or damage sur-
rounding structures because of the limited intracranial cavity and around important
structure tissues, and (2) invasiveness causes incomplete removal of pituitary ade-
noma in neurosurgery to increase risks of complications including recurrence and
poor outcome and need adjuvant therapy (radiotherapy or medications) [1]. How-
ever, the molecular mechanisms of pituitary adenoma invasiveness remain unclear,
although some studies [10] found more vascular evidence in invasive pituitary
adenomas compared to non-invasive tumors to indicate the role of angiogenesis
[10], and some molecular and genetic changes in invasive pituitary adenomas
including downregulation and methylation of CDH13 (H-cadherin) and CDH1
(E-cadherin) [11], loss of death-associated protein kinase and CpG island methyla-
tion [12], and loss of heterozygosity at 11q13 (MEN1 locus) and 13q (retinoblastoma
gene RB locus) without mutation and overexpression of p53 and without homozy-
gous deletions of p15 or p16 [13]. Multiomics analysis is an effective approach to
investigate systematically molecular mechanisms of invasiveness of pituitary ade-
nomas [14–19]. Quantitative transcriptomics analysis [9, 20] identified differen-
tially expressed gene (DEG) profiling (346 DEGs, including 233 upregulated and
Figure 1.
Experimental flow-chart to comparatively study the proteomes between invasive and non-invasive NFPAs.
Reproduced from Zhan et al. [5], with copyright permission from Wiley-VCH, copyright year 2014.
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113 downregulated) between invasive and non-invasive NFPAs. However, protein
and its proteoforms are the functional performer of each gene, proteome is much
more complex than transcriptome, and the coefficient of correlation is very low
(about 0.4) in consistence analysis between proteome and transcriptome for the
same tissue sample [21, 22]. Therefore, it is necessary to use proteomics for pituitary
adenoma invasiveness [23, 24]. A comparative proteomics experiment revealed 30
differentially expressed proteins (DEPs) profiling between invasive and non-
invasive pituitary adenoma tissues [25], however, this study did not distinguish the
functional and non-functional pituitary adenomas (FPAs, and NFPAs). This chap-
ter focused on the proteomic variations and molecular network changes in invasive
relative to noninvasive NFPAs, investigated with two-dimensional gel electropho-
resis (2DGE) coupled with mass spectrometry (MS) and pathway network analysis.
The findings offer the scientific data to discover protein biomarkers for effective
treatment of invasive NFPAs. An experimental flow-chart is shown to study
proteomes between invasive and noninvasive NFPAs (Figure 1).
2. Materials and methods
2.1 2DGE analysis of pituitary adenoma specimen
The invasive (n = 4) and non-invasive (n = 4) NFPA tissues with pathological
diagnosis were used in this study. Each tissue sample was used to individually extract
proteins, and the protein content was quantified. Each tissue sample was analyzed
with 2DGE for 3–4 times [5, 22]. For each 2DGE analysis, 150 μg proteins were used
for isoelectric focusing (IEF) with IPG strips pH 3–10 NL (180  3  0.5 mm). After
IEF, the proteins was reduced and alkalized, and then were separated with the 12%
PAGE resolving gel (250  215  1.0 mm), followed by visualization with modified
silver-staining [26]. The PDQuest 2D gel analysis software (version 7.1.0; Bio-Rad)
was used to digitize and compare 2DGE gel images between invasive and non-
invasive NFPAs. A total of 12 gel images for invasive NFPAs and 12 gel images for
non-invasive NFPAs were used in this analysis to determine each DEPs with a 3-fold
cutoff values and p < 0.05. In addition, four standard proteins, including myoglobin
(17 kDa; p. 7.6), carbonic anhydrase (29 kDa; p. 7.0), ovalbumin (45 kDa; p. 5.1),
and amyloglucosidase (89/70 kDa; p. 3.8), were applied to measure the observed pI
andMr on the 2D gel.
2.2 Mass spectrometry analysis of 2DGE-separated proteins
The protein that contains in gel spot was digested in-gel with trypsin, followed by
ZipTipC18 purification [5, 26]. For LC-ESI-MS/MS analysis, the purified tryptic pep-
tides were eluted in 6 μl of 85% acetonitrile plus 0.1% TFA, air-dried, and then
resuspended in 6 μl of 85% acetonitrile plus 0.1% formic acid. The prepared peptide
samples were analyzed by LC-ESI-qTOFmass spectrometer to obtain MS/MS spec-
trum. For MADI-TOF-MS analysis, the ZipTipC18 peptides were directly eluted on
MALDI platewith 2 μl of а-cyano-4-hydroxycinnamic acid solution (seven cycles), and
dried, and then were analyzed with Voyager DE STRMALDI-TOFmass spectrometer
to obtain peptidemass fingerprint (PMF). TheMS/MS data and PMF datawere used to
search SwissProt database withMascot software for protein identification.
2.3 Bioinformatics
The software NIHDAVID (version 6.7, http://david.abcc.ncifcrf.gov/summary.
jsp) was used to carry out gene-ontology (GO) analysis, including cellular
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components (CC), molecular functions (MF), and biological processes (BP), and
furtherly were categorized into different functional clusters. Ingenuity pathway
analysis (IPA) (www.ingenuity.com) [27] was applied to obtain statistically signif-
icant signaling pathways with identified DEP data between invasive and non-
invasive NFPAs.
3. Results and discussion
3.1 2DE pattern and DEP profile between invasive and noninvasive NFPA
proteomes
Each NFPA tissue sample (four invasive NFPAs and four non-invasive NFPAs)
was analyzed by 2DGE for 3–5 times to guarantee at least three high-quality gel
images. Thus, 24 high-quality 2DGE images (12 gel-images for invasive NFPAs; 12
gel images for non-invasive NFPAs) were obtained. About 1200 spots (an average
of 1172 spots for invasive NFPAs and 1213 spots for non-invasive NFPAs) were
present in each gel image (Figure 2), and most of spots were distributed within
pH 4–9 and Mr 15–150 kDa [21]. The average between-gel matched percentage was
64% (61–67%) among invasive NFPA gels, and 67% (61–69%) among non-invasive
NFPA gels. The positional deviation of the matched-spots was 2.05  0.89 mm
in the IEF direction and 1.41  0.65 mm in the SDS-PAGE direction. For each
sample, the average correlation coefficient (r) of the normalized volumes for
Figure 2.
2DGE map with labeled 4 standard protein markers and 103 spots containing DEPs. IEF was carried out with
18-cm IPGStrip pH 3–10 NL. SDS-PAGE was carried out with 12% polyacrylamide gel. The red means
downregulated protein spot in invasive NFPAs relative to noninvasive NFPAs. The black means upregulated
spot in invasive NFPAs relative to noninvasive NFPAs. Reproduced from Zhan et al. [5], with copyright
permission from Wiley-VCH, copyright year 2014.
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between-gel matched-spots was 0.74 (range, 0.59–0.83), with a best-fit line of:
y = 0.8685x + 0.0804 (r = 0.87; n = 811). The normalized spot volumes between 12
invasive NFPA gels and 12 non-invasive NFPA gels were compared to determine a
differential protein spot with at least 3-fold change and p < 0.05. For example,
Spot-2010 was identified as differential protein spots downregulated in invasive
NFPAs compared to non-invasive NFPAs (Figure 3). With the same approach, 103
differential spots were identified, including 64 upregulated and 39 downregulated
protein spots in invasive NFPAs relative to non-invasive NFPAs (Table 1 and
Figure 1). It clearly demonstrated that the proteome was significantly different
between invasive and non-invasive NFPAs.
Furthermore, each DEP in the differential spot was identified with MS [26]. For
MALDI-TOF-MS PMF analysis, all interfering masses derived from contaminants
including keratins, trypsin, matrix CHCA, and other unknown ones, were removed
from MS spectrum of analyzed sample to obtain a corrected mass list for PMF data
(Figure 4). Those nine masses labeled in Figure 4B were used with MASCOT PMF
search tool to search Swiss-Prot database, and matched to the corresponding tryptic
peptides from 78 kDa glucose-regulated protein (GRP78_HUMAN; P11021)
(Figure 5), which was the DEP identified in the differential Spot-1809. With the
same method, 43 DEPs was identified with PMF analysis (Figure 1 and Table 1).
For LC-ESI-MS/MS analysis, the tryptic peptides were separated by LC and then
sequenced by MS/MS on the qTOF MS instrument, followed by MASCOT MS/MS
data search in the human Swiss-Prot database. For example, six tryptic peptides
from Spot-7604 were sequenced and matched to ATP synthase subunit alpha
(ATPA_HUMAN; P25705) (Figure 6). With the same method, 11 DEPs were
identified with MS/MS data (Figure 1 and Table 1). A total of 57 DEPs, including
30 upregulated and 27 downregulated, were identified in invasive compared to
non-invasive NFPAs (Table 1).
3.2 Functional characteristics of DEPs identified in invasive relative to
noninvasive NFPAs
A total of 54 DEPs out of 57 DEPs were eligible for GO analysis to identify the
significant BPs, CCs, and MFs, which are further grouped with hierarchical cluster
into to functional clusters (Table 2). It clearly demonstrated those DEPs partici-
pated in multiple biological functions to associate with NFPA invasiveness, includ-
ing peptidase and proteolysis, nucleotide metabolism, mitochondrial functions and
oxidative stress, and protein kinase and cell signaling.
A total of 54 DEPs out of 57 DEPs were accepted for IPA pathway-network
analysis to identify significant molecular networks and signaling pathways and
Figure 3.
A presentative differential protein spots between invasive and non-invasive NFPAs (Spot-2010). IPT: Invasive
pituitary tumor. NIPT: Non-invasive pituitary tumor. Reproduced from Zhan et al. [5], with copyright
permission from Wiley-VCH, copyright year 2014.
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Protein name Mr (kDa) pI Fold
Exp. Theor. Exp. Theor.
0011 Q00535 Cyclin-dependent kinase 5 17.56 33.74 4.04 7.57 13.6
0045 P04434 Ig kappa chain V-III region VH
(fragment)
14.35 12.86 4.04 5.63 10.2
0029 P00742/
Q8N4Z0







0101 P23297 Protein S100-A1 21.07 10.54 4.12 4.39 18.6
0411* P04264 Keratin, type II cytoskeletal 1 37.57 66.17 5.05 8.15 5.4
0221 Q5JXM2 Methyltransferase-like protein 24 25.65 41.87 4.71 9.41 4.6
0416 P01040 Cystatin-A 39.04 11.00 5.04 5.38 4.6
0402 Q14314 Fibroleukin 40.94 50.82 4.24 7.08 7.7
0511 P08779/
P04040





1712 P56817 Beta-secretase 1 61.24 56.36 5.25 5.24 8.5
2608 P78536 Disintegrin and metalloproteinase
domain-containing protein 17
52.29 94.56 5.48 5.5 3.5
2133 Q9BYM8 RanBP-type and C3HC4-type zinc finger-
containing protein 1
24.67 59.35 5.52 5.47 6.5
2730 Q8N3R9 MAGUK p55 subfamily member 5 68.52 77.53 5.62 5.77 3.2
2707 Q9Y3B9 RRP15-like protein 66.85 31.64 5.53 5.39 3.6
3308 P29466 Caspase-1 35.79 45.81 5.86 5.63 4.0
3013 P07108 Acyl-CoA-binding protein 13.27 10.04 5.98 6.12 3.5
3512 A2VDF0 Fucose mutarotase 42.54 16.93 5.98 5.49 14.4
4407 Q9UIY3 RWD domain-containing protein 2A 37.06 34.21 6.13 6.01 24.3
4701 Q99797 Mitochondrial intermediate peptidase 65.37 81.38 6.04 6.6 12.4
4615 Q96BJ3 Axin interactor, dorsalization- associated
protein
56.24 35.17 6.25 6.13 3.4
4807 Q16891 Mitochondrial inner membrane protein 80.13 84.03 6.09 6.08 10.6
7014* P18988 Hemoglobin beta-2 chain (PANLE) 16.98 15.93 7.33 7.25 3.4
7021* P06576 ATP synthase subunit beta 12.29 56.56 6.98 5.26 4.2
6313 Q8NA31 Coiled-coil domain-containing protein 79 33.06 84.55 6.92 7.29 3.2
8512 Q8N823 Zinc finger protein 611 41.66 81.39 1.00 9.16 37.4
8513 Q9Y6N3 Calcium-activated chloride channel
regulator family member 3
42.45 30.29 1.00 8.42 3.2
8212* Q9P267/
P01834
Methyl-CpG-binding domain protein 5/






7616* Q9P267 Methyl-CpG-binding domain protein 5 55.37 16.12 7.14 9.17 6.1
1602* A4FU49 SH3 domain-containing protein 21 53.77 70.52 5.13 5.6 7.4
2010 P60983 Glia maturation factor beta 15.82 16.87 5.45 5.19 5.0
2106 P01241/
P02792





1809 P11021 78 kDa glucose-regulated protein 78.19 72.4 5.24 5.07 4.6
2101 P01241 Chain 1: somatotropin 23.95 24.85 5.38 5.29 11.1
6
Proteomics Technologies and Applications
molecular networks. Three molecular networks were identified (Figure 7). The hub
molecules among those three molecular networks included ATPase, MAPK, ERK,
ERK1/2, p38, Jnk, NFkB, AKT, PKA, PKC, EGFR, K-RAS, insulin, UBC, CCND1,
IFNG, NFYB, ESR1, CDK5, calmodulin, and S100A1, which are obviously associ-
ated with cancer biological systems. About 19 statistically significant canonical
pathways were minded from DEPs data (Figure 8), including superoxide radical
degradation, mitochondrial dysfunction, eNOS signaling, inhibition of matrix
metalloprotease, CDK5 signaling, endoplasmic reticulum stress pathway, ketolysis,
ketogenesis, TR/RXR activation, amyloid processing, endothelin-1 signaling,
SSP Swiss-
Prot No.
Protein name Mr (kDa) pI Fold
Exp. Theor. Exp. Theor.
2625 P07332 Tyrosine-protein kinase Fes/Fps 52.98 94.12 5.54 6.27 7.6
4517 Q8TB05 UBA-like domain-containing protein 1 47.39 19.06 6.26 6.14 5.6
3612 Q96QD5 DEP domain-containing protein 7 50.55 58.62 5.88 7.62 4.6
5711 P38405 Guanine nucleotide-binding protein G
(olf) subunit alpha
73.36 44.79 6.49 6.23 4.1
5415 A6NHL2 Tubulin alpha chain-like 3 36.72 50.68 6.56 5.68 10.7
6207* P37285 Kinesin light chain 1 27.69 63.74 6.78 5.73 11.6
5702 P42704 Leucine-rich motif-containing protein,
mitochondrial
73.4 159 6.35 5.81 5.8
6414 Q9UL42 Paraneoplastic antigen Ma2 38.19 41.71 6.8 4.84 10.3
6513 Q9UPQ3 Arf-GAP with GTPase, ANK repeat and
PH domain-containing protein 1
44.44 95.38 6.91 8.18 17.9
6608 Q7Z3I7/
Q9Y6G9
Zinc finger protein 572/cytoplasmic






6603 Q9HD45 Transmembrane 9 superfamily member 3 53.47 68.58 6.68 6.83 22.5
6616* P01859 Ig gamma-2 chain C region 52.36 35.9 6.87 7.66 33.0
7022* P02080 Hemoglobin beta-C 14.09 15.68 7.27 11.58 13.8
7604* P25705 ATP synthase subunit alpha,
mitochondrial
53.63 59.83 6.99 9.16 94.3
7302* Q96CN7 Isochorismatase domain-containing
protein 1
32.25 32.5 6.99 6.96 3.9
7519 Q99542 Chain 1: matrix metalloproteinase-19 43.84 57.36 7.45 7.22 7.0
7802 Q96KP1 Exocyst complex component 2 80.76 105.1 6.98 6.46 16.3
7708 Q02338 D-beta-hydroxybutyrate dehydrogenase,
mitochondrial
72.25 38.53 7.11 9.11 4.9
8503 Q9NPI8 Fanconi anemia group F protein 44.22 42.46 7.53 9.11 8.0
8405 P17066 Heat shock 70 kDa protein 6 38.49 71.44 7.55 5.81 25.6
8409 P25101 Endothelin-1 receptor 41.13 49.89 1.00 8.73 7.6
*It was identified with LC-ESI-MS/MS, and the others with MALDI-TOF-PMF.
Fold (+) means that it is upregulated in invasive relative to noninvasive NFPAs. Fold () means that it is
downregulated in invasive relative to noninvasive NFPAs. Exp. pI = 1.00 means that it was out of the pI range of
standard markers. Reproduced from Zhan et al. [5], with copyright permission from Wiley-VCH, copyright year
2014.
Table 1.
Differentially expressed proteins between invasive and non-invasive NFPAs identified with 2DGE and mass
spectrometry (fold > 3-fold or < 3-fold).
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Figure 4.
All interfering masses from contaminants derived from the margin blank gel on a silver-stained 2D gel map
(A) were removed from MALDI-TOF-MS spectrum derived from the proteins in Spot-1809 (B) to obtain a
corrected mass list for PMF data that were labeled as the symbol *. Reproduced from Zhan et al. [5], with
copyright permission from Wiley-VCH, copyright year 2014.
Figure 5.
Mascot search results from PMF data (Spot-1809). Modified from Zhan et al. [5], with copyright permission
from Wiley-VCH, copyright year 2014.
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Figure 6.
Mascot search results from a representative LC-ESI-MS/MS data from proteins in Spot-7604. Modified from
Zhan et al. [5], with copyright permission from Wiley-VCH, copyright year 2014.
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Category Term Count P-value Proteins (DEPs)
Annotation Cluster 1
GOTERM_BP_FAT Regulation of protein
kinase cascade
5 5.56E  03 P29466, Q96BJ3, P00742, P01241,
P04040
GOTERM_BP_FAT Positive regulation of
signal transduction
5 1.00E  02 P29466, P00742, P01241,
P04040, P78536
GOTERM_BP_FAT Positive regulation of
protein kinase cascade
4 1.22E  02 P29466, P00742, P01241, P04040
GOTERM_BP_FAT Positive regulation of
cell communication










6 1.89E  02 P29466, P00742, Q99542,
Q99797, P56817, P78536
GOTERM_MF_FAT Peptidase activity 6 2.25E  02 P29466, P00742, Q99542,
Q99797, P56817, P78536





3 3.53E  02 Q99542, Q99797, P78536
Annotation Cluster 3
GOTERM_CC_FAT Mitochondrial lumen 5 3.29E  03 Q02338, P06576, P42704, P25705,
Q99797
GOTERM_CC_FAT Mitochondrial matrix 5 3.29E  03 Q02338, P06576, P42704, P25705,
Q99797
GOTERM_CC_FAT Mitochondrial part 7 5.08E  03 Q02338, P06576, P42704, P25705,
Q99797, P04040, Q16891
GOTERM_CC_FAT Organelle envelope 7 6.20E  03 Q02338, P06576, P42704, P25705,
P04040, P25101, Q16891








5 2.67E  02 Q02338, P06576, P25705,
P04040, Q16891
GOTERM_CC_FAT Organelle membrane 8 2.68E  02 Q02338, P06576, P42704, P25705,
P11021, P04040, P25101, Q16891
GOTERM_CC_FAT Mitochondrial
membrane part
3 4.58E  02 P06576, P25705, Q16891
GOTERM_CC_FAT Mitochondrial inner
membrane
4 5.06E  02 Q02338, P06576, P25705, Q16891
Annotation Cluster 4
GOTERM_BP_FAT Response to organic
substance
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Category Term Count P-value Proteins (DEPs)
GOTERM_BP_FAT Proteolysis 8 2.92E  02 P29466, P00742, Q99542,
Q9BYM8, Q99797, P04264,
P56817, P78536
GOTERM_BP_FAT Protein processing 3 4.13E  02 P29466, Q99797, P04264
GOTERM_BP_FAT Protein maturation 3 4.81E  02 P29466, Q99797, P04264
Annotation Cluster 6
GOTERM_BP_FAT Response to alkaloid 3 1.05E  02 Q00535, P38405, P25101
GOTERM_BP_FAT Response to organic
substance
7 1.63E  02 P29466, Q00535, P01241, P38405,
P25101, P17066, P78536
GOTERM_BP_FAT Positive regulation of
molecular function
6 2.56E  02 Q00535, P01241, P38405,
P04040, P25101, P78536
GOTERM_BP_FAT Positive regulation of
protein kinase activity
4 2.61E  02 Q00535, P01241, P25101, P78536
GOTERM_BP_FAT Positive regulation of
protein amino acid
phosphorylation
3 2.71E  02 P01241, P25101, P78536
GOTERM_BP_FAT Positive regulation of
kinase activity
4 2.86E  02 Q00535, P01241, P25101, P78536
GOTERM_BP_FAT Positive regulation of
transferase activity
4 3.15E  02 Q00535, P01241, P25101, P78536
GOTERM_BP_FAT Positive regulation of
phosphorylation
3 3.18E  02 P01241, P25101, P78536
GOTERM_BP_FAT Positive regulation of
phosphate metabolic
process
3 3.36E  02 P01241, P25101, P78536
GOTERM_BP_FAT Positive regulation of
phosphorus metabolic
process
3 3.36E  02 P01241, P25101, P78536
GOTERM_BP_FAT Response to organic
cyclic substance
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semaphoring signaling in neurons, axonal guidance signaling, neuregulin signaling,
and primary immunodeficiency signaling [5]. Also, 10 significant toxicological
events were identified with those DEP data, including mitochondrial dysfunction,
decreased permeability transition/transmembrane potential/depolarization of
mitochondria and mitochondrial membrane, anti-oxidative response panel, and
TR/RXR activation. Our previous studies also revealed that MAPK-signaling
Category Term Count P-value Proteins (DEPs)




GOTERM_MF_FAT Calcium ion binding 7 4.37E  02 P06576, P00742, Q9Y6N3,
Q99542, P23297, P11021, Q99797
Annotation Cluster 10
GOTERM_CC_FAT Cell surface 5 1.45E  02 P06576, P00742, P11021, P56817,
P78536
Modified from Zhan et al. [5], with copyright permission from Wiley-VCH, copyright year 2014.
Table 2.
The functional categories of 54 DEPs identified by GO analysis.
Figure 7.
Significant molecular networks changed in invasive NFPAs. (A) Network 1 functioned in inflammatory disease
and inflammatory response. (B) Network 2 functioned in tumor morphology, cancer, cell-to-cell signaling, and
interaction. (C) Network 3 functioned in tissue morphology, nervous system development and function, and
organismal development. A black solid edge means a direct relationship. A black unsolid edge means an indirect
relationship. A red node means upregulated proteins. A green node means downregulated proteins. Reproduced
from Zhan et al. [5], with copyright permission from Wiley-VCH, copyright year 2014.
12
Proteomics Technologies and Applications
abnormality, oxidative stress, mitochondrial dysfunction, and TR/RXR activation
are significantly associated with NFPAs and invasive NFPAs [27], and the changed
molecule-pattern in each pathway-system was different between NFPA and inva-
sive NFPA, which might contribute to the pathological processes of invasive
NFPAs. Furthermore, ketogenesis and ketolysis, proteolysis abnormality, amyloid
processing, and CDK5 signaling abnormality were also obviously related to invasive
NAPFs. Therefore MAPK-signaling abnormality, mitochondrial dysfunction, TR/
RXR activation, oxidative stress, proteolysis abnormality, CDK5 signaling abnor-
mality, ketogenesis and ketolysis, and amyloid processing were significantly associ-
ated with invasive characteristics of invasive NFPAs, and pathway-network-based
molecule patterns benefit to identify reliable biomarkers for invasive NFPAs.
4. Conclusions
Invasiveness is serious clinical problem in human pituitary adenomas. It is nec-
essary to clarify its molecular mechanisms and discover effective biomarkers to
guide management of invasive NFPAs. This 2DGE-based comparative proteomics
and bioinformatics successfully identified proteomic variation profiling and
pathway-network changes in human invasive NFPAs compared to noninvasive
NFPAs, found 103 differential protein spots (64 upregulated and 39
downregulated) in invasive versus noninvasive NFPA 2DE maps, and identified 57
DEPs (30 upregulated and 27 downregulated), which are significantly involved in
pathogenetic process of invasive NFPAs, with altered pathway networks including
MAPK-signaling abnormality, oxidative stress, mitochondrial dysfunction, keto-
genesis and ketolysis, CDK5 signaling abnormality, TR/RXR activation, proteolysis
abnormality, and amyloid processing. Moreover, some important hub-molecules
were identified to associate with cancer biological processes, including ATPase,
Figure 8.
Statistically significant canonical pathways to involve DEPs in invasive NFPAs. Modified from Zhan et al. [5],
with copyright permission from Wiley-VCH, copyright year 2014.
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MAPK, ERK, ERK1/2, p38, Jnk, NFkB, AKT, PKA, PKC, EGFR, K-RAS, insulin,
UBC, CCND1, IFNG, NFYB, ESR1, CDK5, calmodulin, and S100A1. Those DEPs,
changed pathway networks, and hub-molecules provided new insights into molec-
ular mechanisms of NFPA invasiveness, and important resource for discovery of
effective biomarkers to guide the management of invasive NFPAs.
Acknowledgements
The authors acknowledge the financial supports from the Hunan Provincial
“Hundred Talent Plan” program (to X.Z.), the Xiangya Hospital Funds for Talent
Introduction (to X.Z.), the Hunan Provincial Natural Science Foundation of China
(Grant No. 14JJ7008 to X.Z.), China “863” Plan Project (Grant No. 2014AA020610-1
to X.Z.), and the National Natural Science Foundation of China (Grant No. 81572278
and 81272798 to X.Z.). The scientific contributions of Dr. Dominic M. Desiderio from
University of Tennessee Health Science Center were also acknowledged.
Conflict of interest
We declare that we have no financial and personal relationships with other
people or organizations.
Author’s contributions
X.Z. conceived the concept, designed the book chapter, and wrote and critically
revised the book chapter, coordinated and was responsible for the correspondence
work and financial support. X.H.Z and X.W participated in experiments. X.H.Z




DEP differentially expressed protein
ESI electrospray ionization
FPA functional pituitary adenomas
IEF isoelectric focusing
IPA ingenuity pathway analysis
IPG immobilized pH gradient
LC liquid chromatography
MALDI matrix-assisted laser desorption/ionization
MF molecular functions
Mr relative mass
MRI magnetic resonance imaging
MS mass spectrometry
MS/MS tandem mass spectrometry
NFPA nonfunctional pituitary adenoma
pI isoelectric point
PMF peptide mass fingerprint
SDS-PAGE sodium dodecyl sulfate-polyacrylamide gel electrophoresis
TOF time-of-flight
2DGE two-dimensional gel electrophoresis
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